Drug intelligence / Profile preview

VT-1908

Development stage: Preclinical
Lead developer: Vyome Therapeutics
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

VT-1908 is an investigational small molecule drug developed by Vyome Therapeutics. It acts as an **inosine monophosphate dehydrogenase inhibitor** and is being developed primarily for the treatment of uveitis, a non-infectious eye disorder. VT-1908 represents a new molecular entity within the class of anti-inflammatories and therapies for eye disorders. As of August 2024, it is in preclinical development, with plans to initiate phase I clinical trials and file an IND application for uveitis. There is no orphan drug status associated with this molecule[1][3].

Other names: VT-1908VT1908VT 1908

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)

Beyond the preview

Go deeper on VT-1908.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT-1908.

Explore the full profile